Cyclerion Therapeutics, Inc. (CYCN) Discusses On Pioneering A New Era In Neuropsychiatric Therapies Call (Transcript) [Seeking Alpha]
Cyclerion Therapeutics, Inc. (CYCN)
Company Research
Source: Seeking Alpha
Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property. A copy of this release and presentation to accompany this call are available on the Investor Relations section of our website at ir.cyclerion.com. I am Regina Graul, Chief Executive Officer of Cyclerion Therapeutics. Thank you for joining us for the Cyclerion overview. Today, we'll share our strategy for building a new era in neuropsychiatric therapies, highlight the opportunities ahead and walk through our clinical and corporate road map. Before we get started, I would like to remind everyone that certain matters discussed in this presentation are forward-looking statements. We may, in some cases, use terms such as potential, may, expects, plans, could, opp
Show less
Read more
Impact Snapshot
Event Time:
CYCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCN alerts
High impacting Cyclerion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYCN
News
- Cyclerion Therapeutics (NASDAQ:CYCN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network [Yahoo! Finance]Yahoo! Finance
- Cyclerion Therapeutics, Inc. - Pre Recorded Special Call [Seeking Alpha]Seeking Alpha
- Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company [Yahoo! Finance]Yahoo! Finance
- Cyclerion Announces Transformational Relaunch as a Neuropsychiatric CompanyGlobeNewswire
CYCN
Sec Filings
- 12/1/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 10-K/A
- CYCN's page on the SEC website